Cargando…
Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction
AIM: To comprehensively evaluate mitochondrial (dys) function in preclinical models of nonalcoholic steatohepatitis (NASH). METHODS: We utilized two readily available mouse models of nonalcoholic fatty liver disease (NAFLD) with or without progressive fibrosis: Lep(ob)/Lep(ob) (ob/ob) and FATZO mice...
Autores principales: | Boland, Michelle L, Oldham, Stephanie, Boland, Brandon B, Will, Sarah, Lapointe, Jean-Martin, Guionaud, Silvia, Rhodes, Christopher J, Trevaskis, James L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922994/ https://www.ncbi.nlm.nih.gov/pubmed/29713129 http://dx.doi.org/10.3748/wjg.v24.i16.1748 |
Ejemplares similares
-
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
por: Jouihan, Hani, et al.
Publicado: (2017) -
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
por: Boland, Michelle L., et al.
Publicado: (2020) -
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
por: Boland, Michelle L, et al.
Publicado: (2019) -
Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012) -
Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis
por: Ozawa, Yusuke, et al.
Publicado: (2018)